| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 30/10/2006 | 17:34 | Business Wire | Covalent Group Changes Name to Encorium Group, Inc. | NASDAQ:CVGR | Covalent |
| 20/10/2006 | 22:08 | Business Wire | Covalent Group, Inc. Announces Results of Shareholder Vote | NASDAQ:CVGR | Covalent |
| 19/10/2006 | 14:01 | Business Wire | Covalent Signs $8.2 Million in Contracts For Multinational Studies to Treat Influenza | NASDAQ:CVGR | Covalent |
| 08/08/2006 | 22:36 | Business Wire | Covalent Reports 2006 Second Quarter Financial Results; Company to Hold Conference Call at 9:00 AM on Wednesday, August 9, 2006 | NASDAQ:CVGR | Covalent |
| 07/08/2006 | 14:24 | Business Wire | Covalent Group, Inc. Announces $1.7 Million Contract For Phase 2 Clinical Trial in Atherosclerosis | NASDAQ:CVGR | Covalent |
| 02/08/2006 | 16:14 | Business Wire | Covalent Group, Inc. Schedules Second Quarter Financial Results and Conference Call | NASDAQ:CVGR | Covalent |
| 13/07/2006 | 18:00 | Business Wire | Covalent Group, Inc. Signs Contracts Totaling $1.5 Million for Clinical Studies Offering Advanced Therapeutic Approaches to Pat | NASDAQ:CVGR | Covalent |
| 06/07/2006 | 20:15 | Business Wire | Covalent Group Amends Business Combination Agreement with Remedium Oy | NASDAQ:CVGR | Covalent |
| 28/06/2006 | 14:27 | Business Wire | Covalent Group, Inc. Announces $2.1 Million of New Business Contracts; Reiterates Second Quarter Guidance | NASDAQ:CVGR | Covalent |
| 15/05/2006 | 23:22 | Business Wire | Covalent Reports 2006 First Quarter Financial Results and Summary Balance Sheet Data; Company to Hold Conference Call at 9:00 A | NASDAQ:CVGR | Covalent |
| 08/05/2006 | 14:12 | Business Wire | Covalent Group, Inc. Schedules First Quarter Financial Results and Conference Call | NASDAQ:CVGR | Covalent |
| 20/04/2006 | 14:07 | Business Wire | Covalent Group, Inc. Signs $1 Million Contract To Conduct Phase 1 Study of Drug to Prevent/Treat Infectious Disease | NASDAQ:CVGR | Covalent |
| 30/03/2006 | 15:00 | Business Wire | Covalent Group, Inc. Announces Additional New Business Contracts | NASDAQ:CVGR | Covalent |
| 21/03/2006 | 23:15 | Business Wire | Covalent Group, Inc. Announces $2.1 Million Contract To Conduct Patient Disease Registry In Hospitalized Subjects With Hyponatr | NASDAQ:CVGR | Covalent |
| 21/03/2006 | 23:14 | Business Wire | Covalent Group, Inc. Signs $1.3 Million in Consulting and Medical Writing Contracts to Support New Drug Applications (NDA) for | NASDAQ:CVGR | Covalent |
| 21/03/2006 | 23:12 | Business Wire | Covalent Reports 2005 Fourth Quarter and Year End Financial Results and Summary Balance Sheet Data; Company to Hold Conference | NASDAQ:CVGR | Covalent |
| 16/03/2006 | 13:57 | Business Wire | Covalent Group, Inc. Schedules Fourth Quarter Financial Results and Conference Call | NASDAQ:CVGR | Covalent |
| 03/03/2006 | 14:12 | Business Wire | Covalent Group, Inc. Enters into Combination Agreement with Remedium Oy; Conference Call Scheduled for 11:00 AM ET Today | NASDAQ:CVGR | Covalent |
| 08/02/2006 | 15:31 | Business Wire | Covalent Group, Inc. and Sudler & Hennessey Announce Strategic Partnership to Design and Conduct Global Patient Disease Registri | NASDAQ:CVGR | Covalent |
| 02/02/2006 | 14:01 | Business Wire | Covalent Group, Inc. Signs $2.2 Million Contract With New Sponsor to Conduct Clinical Trial in Patients with Cardiovascular Dise | NASDAQ:CVGR | Covalent |
| 31/01/2006 | 18:00 | Business Wire | Covalent Group, Inc. Retains The Equity Group to Provide Investor Relations Services | NASDAQ:CVGR | Covalent |
| 24/01/2006 | 14:00 | PR Newswire (US) | Covalent Group, Inc. Announces Multiple New Business Contracts with an Aggregate Value of $1.0 Million | NASDAQ:CVGR | Covalent |
| 18/01/2006 | 14:00 | PR Newswire (US) | Covalent Group, Inc. Signs Contract for $2.3 Million to Conduct a Multinational Phase 2 Clinical Trial Involving a New Antithrom | NASDAQ:CVGR | Covalent |
| 08/12/2005 | 13:00 | PR Newswire (US) | Covalent Group, Inc. Signs Letter-of-Intent to Conduct $2.2 Million Multinational Phase 2 Clinical Trial in Cardiovascular Disea | NASDAQ:CVGR | Covalent |
| 05/12/2005 | 13:01 | PR Newswire (US) | Covalent Group, Inc. and Emergent BioSolutions Sign Contract to Develop Immune Globulins for Treatment Exposure of Anthrax Infec | NASDAQ:CVGR | Covalent |
| 18/11/2005 | 15:30 | PR Newswire (US) | CSC's DVC Reaches Milestone in Plague Vaccine Clinical Trial | NASDAQ:CVGR | Covalent |
| 11/11/2005 | 16:20 | PR Newswire (US) | /C O R R E C T I O N -- Covalent Group, Inc. / | NASDAQ:CVGR | Covalent |
| 10/11/2005 | 23:01 | PR Newswire (US) | Covalent Reports Results for Third Quarter 2005 | NASDAQ:CVGR | Covalent |
| 07/11/2005 | 14:03 | PR Newswire (US) | Covalent Group, Inc. to Report Third Quarter 2005 Results on Thursday, November 10 | NASDAQ:CVGR | Covalent |
| 06/10/2005 | 15:01 | PR Newswire (US) | Covalent Group, Inc. Announces $5.3 Million Contract to Provide Additional Services for a Global Phase 3 Trial in Hypertension | NASDAQ:CVGR | Covalent |